11-hydroxyyohimbine has been researched along with yohimbine in 5 studies
| Studies (11-hydroxyyohimbine) | Trials (11-hydroxyyohimbine) | Recent Studies (post-2010) (11-hydroxyyohimbine) | Studies (yohimbine) | Trials (yohimbine) | Recent Studies (post-2010) (yohimbine) |
|---|---|---|---|---|---|
| 5 | 1 | 0 | 5,893 | 253 | 532 |
| Protein | Taxonomy | 11-hydroxyyohimbine (IC50) | yohimbine (IC50) |
|---|---|---|---|
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0353 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1.02 | |
| D(2) dopamine receptor | Homo sapiens (human) | 2.06 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0428 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0466 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.126 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.013 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.126 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.074 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 1.689 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berlan, M; Galitzky, J; Le Corre, P; Le Verge, R | 1 |
| Chevanne, F; Le Corre, PA; Le Verge, R; Peskind, ER; Raskind, MA | 1 |
| Chevanne, F; Dollo, G; Le Corre, P; Le Verge, R | 1 |
| Duflos, A; Fahy, J; Jacquesy, JC; Jouannetaud, MP; Redoules, F | 1 |
| Flockhart, DA; Ho, H; Insel, PA; Kailasam, MT; Kennedy, BP; Le Corre, P; Leverge, R; O'connor, DT; Parmer, RJ; Schork, NJ; Skaar, TP; Smith, DW; Ziegler, MG | 1 |
1 trial(s) available for 11-hydroxyyohimbine and yohimbine
| Article | Year |
|---|---|
Biopharmaceutics and metabolism of yohimbine in humans.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Area Under Curve; Humans; Injections, Intravenous; Male; Yohimbine | 1999 |
4 other study(ies) available for 11-hydroxyyohimbine and yohimbine
| Article | Year |
|---|---|
Alpha 2-adrenoceptor antagonist potencies of two hydroxylated metabolites of yohimbine.
Topics: Adipose Tissue; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Blood Platelets; Blood Proteins; Brimonidine Tartrate; Cell Membrane; Dioxanes; Epinephrine; Humans; Hydroxylation; Idazoxan; In Vitro Techniques; Lipolysis; Male; Platelet Aggregation; Protein Binding; Quinoxalines; Yohimbine | 1993 |
Cerebrospinal fluid and plasma disposition of yohimbine and 11-hydroxy-yohimbine in young and older healthy subjects, and Alzheimer's disease patients.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Aging; Alzheimer Disease; Female; Humans; Male; Middle Aged; Norepinephrine; Receptors, Adrenergic, alpha-2; Reference Values; Yohimbine | 1997 |
Hydroxylation of yohimbine in superacidic media: one-step access to human metabolites 10 and 11-hydroxyyohimbine.
Topics: Chemistry, Organic; Humans; Hydrofluoric Acid; Hydroxylation; Magnetic Resonance Spectroscopy; Models, Chemical; Yohimbine | 2001 |
Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Analysis of Variance; Biological Availability; Blood Pressure; Case-Control Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Ethnicity; Female; Genotype; Humans; Hypertension; Infusions, Intravenous; Male; Metabolic Clearance Rate; Polymorphism, Genetic; Receptors, Adrenergic, alpha-2; Sensitivity and Specificity; Vascular Resistance; Yohimbine | 2004 |